LDK378 vs Chemo in ALK+ NSCLC in patients who failed crizotinib

• Research type

  Research Study

• Full title

  A phase III, multicenter, randomized, open-label study of oral LDK378 versus standard chemotherapy in adult patients with ALK-rearranged (ALK-positive) advanced non-small cell lung cancer who have been treated previously with chemotherapy (platinum doublet) and crizotinib

• IRAS ID

  133087

• Contact name

  Samreen Ahmed

• Contact email

  Samreen.Ahmed@uhl-tr.nhs.uk

• Sponsor organisation

  Novartis Pharma Services AG

• Eudract number

  2012-005637-36

• ISRCTN Number

  n/a

• Clinicaltrials.gov Identifier

  n/a

• REC name

  East Midlands - Nottingham 2 Research Ethics Committee

• REC reference

  13/EM/0284

• Date of REC Opinion

  31 Jul 2013

• REC opinion

  Favourable Opinion